Taking ZIRABEV

Main navigation

How will I receive
treatment with ZIRABEV?

ZIRABEV is given by a healthcare provider as an intravenous (IV) infusion. That means you get ZIRABEV through a needle in your vein

If you’ve had surgery you cannot receive ZIRABEV until at least 28 days following surgery and the wound is fully healed

How often do I have
to receive ZIRABEV?

Depending on your specific type of cancer, you may receive ZIRABEV every 2 to 3 weeks with or without additional treatment you may be prescribed

If you have questions about how often you'll receive ZIRABEV, speak with your healthcare team

How long will it take?

If your ZIRABEV infusions are tolerated:

90 minutes: 1st infusion

60 minutes: 2nd infusion

30 minutes: 3rd infusion

30 minutes: Future infusions

NOTE: You always get the same dose of ZIRABEV. If your ZIRABEV infusions are tolerated, they can take as little as 30 minutes.

Metastatic Colorectal Cancer (mCRC)

Every 2 weeks in combination with intravenous fluorouracil-based chemotherapy

Non–Small Cell Lung Cancer (NSCLC)

Every 3 weeks in combination with carboplatin and paclitaxel

Recurrent Glioblastoma (GBM)

Every 2 weeks

Metastatic Renal Cell Carcinoma (mRCC)

Every 2 weeks in combination with interferon alfa

Persistent, Recurrent, or Metastatic Cervical Cancer (CC)

Every 3 weeks in combination with paclitaxel and cisplatin or in combination with paclitaxel and topotecan

Possible serious side effects of ZIRABEV

Everyone reacts differently to ZIRABEV therapy, so it's important to know what the side effects are.

ZIRABEV may cause serious side effects that can be life-threatening. Your doctor will stop treatment if any serious side effects occur.

Be sure to contact your healthcare team if there are any signs of these side effects.

Most serious side effects (not common, but sometimes fatal) include:

GI perforation

A hole that develops in your stomach or intestine. Symptoms include pain in your abdomen, nausea, vomiting, constipation, or fever.

Wounds that don't heal

A cut made during surgery can be slow to heal or may not fully heal. ZIRABEV should not be used for at least 28 days before or after surgery and until surgical wounds are fully healed.

Serious bleeding

This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding. If you recently coughed up blood or had serious bleeding, be sure to tell your doctor.

IMPORTANT SAFETY INFORMATION AND INDICATIONS

IMPORTANT SAFETY INFORMATION

Possible serious side effects

Everyone reacts differently to ZIRABEV therapy, so it's important to know what the side effects are. ZIRABEV may cause serious side effects that can be life-threatening. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your healthcare team if there are any signs of these side effects.

Most serious side effects (not common, but sometimes fatal):

GI perforation. A hole that develops in your stomach or intestine. Symptoms include pain in your abdomen, nausea, vomiting, constipation, or fever

Wounds that don't heal. A cut made during surgery can be slow to heal or may not fully heal. ZIRABEV should not be used for at least 28 days before or after surgery and until surgical wounds are fully healed

Serious bleeding. This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding. If you recently coughed up blood or had serious bleeding, be sure to tell your doctor

Other possible serious side effects

Abnormal passage in the body. This type of passage—known as a fistula—is an irregular connection from one part of the body to another and can sometimes be fatal

Severe high blood pressure. Blood pressure that severely spikes or shows signs of affecting the brain. Blood pressure should be monitored every 2 to 3 weeks while on ZIRABEV and after stopping treatment

Kidney problems. These may be caused by too much protein in the urine and can sometimes be fatal

Infusion-related reactions. These were uncommon with the first dose of bevacizumab (less than 3% of patients); 0.2% of patients had severe reactions. Infusion reactions include high blood pressure or severe high blood pressure that may lead to stroke, trouble breathing, decreased oxygen in red blood cells, a serious allergic reaction, chest pain, headache, tremors, and excessive sweating. Your doctor or nurse will monitor you for signs of infusion reactions

Severe stroke or heart problems. These may include blood clots, mini-stroke, heart attack, chest pain, and your heart may become too weak to pump blood to other parts of your body (congestive heart failure). These can sometimes be fatal

Nervous system and vision problems. Signs include headache, seizure, high blood pressure, sluggishness, confusion, and blindness

Side effects seen most often

In clinical studies across different types of cancer, some patients treated with bevacizumab experienced the following side effects:

High blood pressure

Too much protein in the urine

Nosebleeds

Rectal bleeding

Back pain

Headache

Taste change

Dry skin

Inflammation of the skin

Inflammation of the nose

Watery eyes

ZIRABEV is not for everyone.

Talk to your doctor if you are:

Undergoing surgery. ZIRABEV should not be used for 28 days before or after surgery and until surgical wounds are fully healed

Pregnant, think you are pregnant, planning to become pregnant, or breastfeeding. Data have shown that bevacizumab products may harm your unborn baby. Use birth control while on ZIRABEV. If you stop ZIRABEV, you should keep using birth control for 6 months before trying to become pregnant. Taking bevacizumab products could cause a woman's ovaries to stop working and may impair her ability to have children. Breastfeeding while on bevacizumab products may harm your baby therefore women should not breastfeed during and for 6 months after taking ZIRABEV

INDICATIONS

Metastatic Colorectal Cancer

ZIRABEV is approved to treat metastatic colorectal cancer (mCRC) for:

First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy

Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes a bevacizumab product

ZIRABEV is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.

Non—Small Cell Lung Cancer

ZIRABEV, in combination with carboplatin and paclitaxel, is approved to treat advanced non–squamous non–small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.

Recurrent Glioblastoma

ZIRABEV is approved to treat glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM).

Metastatic Renal Cell Carcinoma

ZIRABEV, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).

Persistent, Recurrent, or Metastatic Cervical Cancer

ZIRABEV, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.

If you have any questions about your condition or treatment, talk to your doctor.

Patients should always ask their doctors for medical advice about adverse events.

You may report an adverse event related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where healthcare professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit MedWatch or call 1-800-FDA-1088.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

You are leaving this website

Links to all outside websites are provided as a convenience to our visitors and do not imply an endorsement or recommendation by Pfizer. Pfizer accepts no responsibility or liability for the content or services of other websites.